CIK 0001478320 · Large accelerated filer
Adaptive Biotechnologies Corp
Sign in to watch- Ticker
- ADPT
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- WA
- Entity type
- operating
- EIN
- 270907024
- Phone
- 206-659-0067
- Business address
- 1165 EASTLAKE AVE E, SEATTLE, WA, 98109
- Former names
- Adaptive TCR Corp
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $33,491,115
- in 20 filings, $14.5M under 10b5-1 plans
Net −$33,491,115. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-02-14 | ROBINS CHAD M CEO and Chairman | Option exercise 10b5-1 | +158,921 | $6.32 | $1.0M | 2,735,622 |
| 2025-02-14 | ROBINS CHAD M CEO and Chairman | Sale 10b5-1 | −158,921 | $8.46 | $1.3M | 2,576,701 |
| 2025-02-14 | ROBINS CHAD M CEO and Chairman | Option exercise · Stock Option (right to buy) 10b5-1 | −158,921 | 496,347 | ||
| 2025-02-13 | ROBINS CHAD M CEO and Chairman | Option exercise 10b5-1 | +100,287 | $6.32 | $634K | 2,676,988 |
| 2025-02-13 | ROBINS CHAD M CEO and Chairman | Sale 10b5-1 | −100,287 | $8.44 | $846K | 2,576,701 |
| 2025-02-13 | ROBINS CHAD M CEO and Chairman | Option exercise · Stock Option (right to buy) 10b5-1 | −100,287 | 655,268 | ||
| 2024-11-18 | PISKEL KYLE Chief Financial Officer | Sale | −248 | $4.98 | $1K | 154,330 |
| 2024-10-08 | BOBULSKY SUSAN Chief Commercial Officer, MRD | Option exercise | +5,000 | $1.98 | $10K | 253,290 |
| 2024-10-08 | BOBULSKY SUSAN Chief Commercial Officer, MRD | Option exercise · Stock Option (right to buy) | −5,000 | 0 | ||
| 2024-08-22 | Taylor Stacy L SVP and General Counsel | Sale 10b5-1 | −26,922 | $4.50 | $121K | 139,365 |
| 2024-05-15 | PISKEL KYLE Chief Financial Officer | Grant or award | +31,260 | 154,578 | ||
| 2024-03-12 | NEUPERT PETER M Director | Option exercise | +15,000 | $0.84 | $13K | 169,296 |
| 2024-03-12 | NEUPERT PETER M Director | Option exercise · Stock Option (right to buy) | −15,000 | 0 | ||
| 2024-03-05 | PISKEL KYLE Principal Accounting Officer | Sale | −7,727 | $3.43 | $27K | 123,318 |
| 2024-03-05 | Taylor Stacy L SVP and General Counsel | Sale | −6,772 | $3.43 | $23K | 172,896 |
| 2024-03-05 | Taylor Stacy L SVP and General Counsel | Sale | −6,609 | $3.44 | $23K | 166,287 |
| 2024-03-05 | LO FRANCIS Chief People Officer | Sale | −12,887 | $3.43 | $44K | 255,558 |
| 2024-03-05 | LO FRANCIS Chief People Officer | Sale | −1,813 | $3.44 | $6K | 253,745 |
| 2024-03-05 | BENZENO SHARON Chief Commercial Ofc Imm Med | Sale | −10,746 | $3.43 | $37K | 346,059 |
| 2024-03-05 | BENZENO SHARON Chief Commercial Ofc Imm Med | Sale | −18,644 | $3.44 | $64K | 327,415 |
Page 29 of 120 · 2,386 trades